Fulcrum Therapeutics, Inc. (FULC)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Fulcrum Therapeutics, Inc. (FULC) is down 72.2% since the beginning of the year. At $3 per share, FULC is trading 80.1% below its 52-week high of $16. Investors who bought $1,000 worth of FULC shares 5 years ago would now be looking at an investment worth $388.

Fulcrum Therapeutics, Inc. (FULC) has returned -72.24% so far this year and -54.89% over the past 12 months.

Based on dividend-adjusted daily data since Jul 18, 2019, FULC's average daily return is +0.16%, while the average monthly return is +5.43%. At this rate, an investment would double in approximately 1.1 years.

Historically, 48% of months were positive and 52% were negative. The best month was Aug 2021 with a return of +306.3%, while the worst month was Apr 2022 at -59.3%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 6 months.

On a daily basis, FULC closed higher 48% of trading days. The best single day was Aug 10, 2021 with a return of +125.3%, while the worst single day was Sep 12, 2024 at -61.1%.

Fulcrum Therapeutics, Inc. has an annualized alpha of 19.10%, beta of 1.51, and R2 of 0.07 versus S&P 500 Index. Calculated based on daily prices since July 19, 2019.

• This stock participated in 198.52% of S&P 500 Index downside but only 93.80% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.07 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

FULC ranks 15 for risk / return — in the bottom 15% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for Fulcrum Therapeutics, Inc. (FULC) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Fulcrum Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Fulcrum Therapeutics, Inc. was 92.70%, occurring on Apr 12, 2023. The portfolio has not yet recovered.

The current Fulcrum Therapeutics, Inc. drawdown is 89.86%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Fulcrum Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Fulcrum Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.